The Crispr-Cas9 patent tussle continues: The case of UC Berkeley at the EPO – Lexology
Posted: November 15, 2019 at 10:45 pm
In Europe, we dont do things the way the Americans do
Oral proceedings in the opposition against UC Berkeleys (UCs) main European patent EP2800811 are scheduled for all of three (!) days in February of 2020 at the European Patent Office (EPO). The opposition divisions (ODs) preliminary and non-binding opinion, provided on the 30th of August 2019 in preparation for the hearing, is favorable to the patentee. In its opinion, the OD sides with UC Berkeley and dismisses the main arguments of the seven opponents. Arguments relating to minor issues of added subject matter have been accepted by the OD, however UC is likely to be able to overcome these. Thus, there is a chance that UC Berkeley will keep their strong hold on rights to general platform Crispr technology in Europe.
UC Berkeleys patent claims priority from four provisional US applications. The question of whether the priority from the first provisional application P1 is valid or not lies at heart of the case.
According to European practice, G2/98, the requirements of claiming priority of the same invention in the meaning of Art 87(1) EPC mean that priority can only be acknowledged if the skilled person can derive the subject matter directly and unambiquously, using common general knowledge (CGK), from the previous application as a whole. In addition, the priority document must provide an enabling disclosure, in other words, all essential elements needed to carry out the invention must be disclosed in the priority document.
The opponents argue that P1 fails to provide an enabling disclosure, as it does not disclose or exemplify elements which are essential for the workability of the Crispr-Cas9 system in eukaryotic cells. At the heart of this issue is the protospacer adjacent motif (PAM), a 2-6 base pair DNA sequence which immediately follows the target DNA sequence and is an essential targeting component. The opponents argue that without knowledge of a PAM sequence, a person skilled in the art was not in a position to design an appropriate guide RNA and would therefore not have been able to achieve cleavage of target DNA (as the Cas9 endonuclease will not recognize target DNA without the PAM).
UC replies that the requirement of a PAM to be located downstream of the target DNA sequence was CGK at the date of filing of P1 and therefore the omission of any reference to PAM is of no detriment to the disclosure of P1. UC states that the skilled persons understanding of this was confirmed by the sequences disclosed in P1, wherein the amino acid sequences corresponding to PAMs are present immediately downstream of the target DNA.
If the priority claim from P1 is found to be invalid, the effective date of the patent at hand would be after UCs scientific paper on Crispr-Cas9 was published in Science. This would be detrimental to the patentability of at least some of the claims.
However, UC was successful during the examination before the EPO, as well as in the corresponding UK cases, in arguing that PAM was part of CGK. By accepting in their preliminary opinion that PAM was part of the CGK at the time of filing of P1, the OD has provisionally concluded that the disclosure of P1 is enabling over the whole claim scope, encompassing eukaryotic applications.
Concerning what actually was CGK at the time, UC argues that CGK was represented by review and research articles in the fast-evolving new technology area. UC holds that such articles confirm that the requirement for PAM in the target DNA was CGK. Although full of references to CGK and the skilled person, the preliminary opinion does not dwell on the identity of the skilled person. Establishing the identity of the skilled person is likely to be important during the oral proceedings. Not limited to PAM, the opponents argue that several lines of technical information are missing in P1 and that a skilled person operating within the limits of what is explicitly defined in P1 would be confronted with an inacceptable degree of failure.
The OD has also come to the preliminary view that the claims are novel and exhibit inventive step. The inventive step analysis is based on the problem-solution approach starting from a prior art document from the TALEN field of gene editing, and not from the Crispr-field, based on the purpose of the UC invention. The technical problem solved by the invention is considered to be to provide a more versatile gene editing system. The OD adds that the Examples in the patent show that UCs invention achieves this, or at least renders the achievement credible, also for eukaryotic cells.
UCs position is that P1 not only claimed a new class of endonucleases, but also provided ample guidance on how to use the endonuclease complex for example in eukaryotic systems as, amongst other things, P1 disclosed expression systems including vectors suitable for eukaryotic expression. They point to the fact that several groups in the scientific community quickly, upon publication of the Science paper, confirmed that the Crisp-Cas9 system could be used for gene editing in eukaryotic cells.
Interestingly, the OD takes no notice of UC inventors Doudnas and Charpentiers public statements, made upon publishing of the Science paper, about unpredictability and technical challenges of adapting the Crispr-Cas9 system to eukaryotic gene editing. In fact, the OD underlines the difference between the question of obviousness in the US interference proceedings by exclaiming under US law! in the opinion and the question of plausibility in the present case. Although plausibility is not a term used in the European Patent Convention, it is increasingly more discussed. According to case law, however, the question of plausibility only comes into play if experimental data is lacking. The OD states in its opinion that this does not apply to present case, because the disclosure does contain experimental data.
Nevertheless, plausibility, as well as the identity of the skilled person, are likely to be discussed during the oral proceedings. Is the skilled person going to be someone from the TALEN field? If so, would they be expected to know all the details and nuances of the Crispr-Cas9 field or not? The identity of the skilled person may have implications on several aspects of the case.
For now, it appears that the differences between the European and US patent landscape in the Crispr-Cas9 field may remain, at least as indicated by the non-binding and preliminary opinion of the OD.
See the rest here:
The Crispr-Cas9 patent tussle continues: The case of UC Berkeley at the EPO - Lexology
- 'CRISPR pill' instructs harmful bacteria to self-destruct - National Hog Farmer [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- Highly sensitive CRISPR diagnostic tool created - BioNews [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- More Tooth, More Tail in CRISPR Operations | GEN - Genetic Engineering & Biotechnology News (press release) [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- Quick, Sensitive Diagnostic Tests with CRISPR - Technology Networks [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- MPEG LA Invites CRISPR-Cas9 Patents to be Pooled in a One-Stop License - Yahoo Finance [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- What Is CRISPR? - livescience.com [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- CRISPR and Stem Cells Identify Novel Chlamydia Drug Targets - Genetic Engineering & Biotechnology News [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- CRISPR webinar: HGF discusses IP landscape - Life Sciences Intellectual Property Review (subscription) [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- CRISPR.com was for sale, and you won't guess who bought it - STAT [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- CRISPR Pill May Be Key in Fight Against Antibiotic Resistance - Singularity Hub [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- Intellia (NTLA), CRISPR Therapeutics (CRSP) Receive U.S. Patent for CRISPR/Cas9 Ribonucleoprotein Complexes - StreetInsider.com [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- transOMIC technologies Launches transEDIT-dual CRISPR ... - PR Newswire (press release) [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- Global CRISPR Market Forecast 2017-2025 - Research and Markets ... - Business Wire (press release) [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- Quick, Sensitive Diagnostic Tests with CRISPR | Technology Networks - Technology Networks [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- CRISPR/Cas9 and Targeted Genome Editing: A New Era in ... [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- CRISPR - Wikipedia [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- CRISPR Used To Modify Multiple Genes In Rice - Asian Scientist Magazine [Last Updated On: April 28th, 2017] [Originally Added On: April 28th, 2017]
- Current CRISPR Patent Dispute, Explained - CALIFORNIA [Last Updated On: April 28th, 2017] [Originally Added On: April 28th, 2017]
- CEOs of top gene-editing firms got huge compensation hikes last year - Boston Business Journal [Last Updated On: April 28th, 2017] [Originally Added On: April 28th, 2017]
- CRISPR-SMART Cells Regenerate Cartilage, Secrete Anti-Arthritis Drug - Genetic Engineering & Biotechnology News [Last Updated On: April 29th, 2017] [Originally Added On: April 29th, 2017]
- Another CRISPR Trial Begins - GenomeWeb [Last Updated On: April 29th, 2017] [Originally Added On: April 29th, 2017]
- China Is Racing Ahead of the US in the Quest to Cure Cancer With CRISPR - Gizmodo [Last Updated On: April 29th, 2017] [Originally Added On: April 29th, 2017]
- CRISPR Gene Editing - CRISPR/Cas9 - Horizon Discovery [Last Updated On: May 1st, 2017] [Originally Added On: May 1st, 2017]
- CRISPR | Broad Institute [Last Updated On: May 1st, 2017] [Originally Added On: May 1st, 2017]
- Questions and Answers about CRISPR | Broad Institute [Last Updated On: May 1st, 2017] [Originally Added On: May 1st, 2017]
- CRISPR Genome Engineering Resources | learn, share, and discuss [Last Updated On: May 1st, 2017] [Originally Added On: May 1st, 2017]
- CRISPR Technology Scientists on Their Gene Editing Tool - TIME [Last Updated On: May 1st, 2017] [Originally Added On: May 1st, 2017]
- Cas9 - Wikipedia [Last Updated On: May 1st, 2017] [Originally Added On: May 1st, 2017]
- Using CRISPR against cancer shows success in mice - Futurity - Futurity: Research News [Last Updated On: May 2nd, 2017] [Originally Added On: May 2nd, 2017]
- Using CRISPR to Find Treatments for Aggressive Pediatric Brain Cancer - Bioscience Technology [Last Updated On: May 2nd, 2017] [Originally Added On: May 2nd, 2017]
- CRISPR Eliminates HIV in Live Animals - Genetic Engineering & Biotechnology News [Last Updated On: May 2nd, 2017] [Originally Added On: May 2nd, 2017]
- The CRISPR patent dispute - Europe and the US - BioNews [Last Updated On: May 2nd, 2017] [Originally Added On: May 2nd, 2017]
- How Scientists Think CRISPR Will Change Medicine - TIME [Last Updated On: May 3rd, 2017] [Originally Added On: May 3rd, 2017]
- What you need to know about the legal battle over CRISPR patents - Genetic Literacy Project [Last Updated On: May 4th, 2017] [Originally Added On: May 4th, 2017]
- Scientists have eliminated HIV in mice using CRISPR - TechCrunch [Last Updated On: May 4th, 2017] [Originally Added On: May 4th, 2017]
- CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer ... - GlobeNewswire (press release) [Last Updated On: May 4th, 2017] [Originally Added On: May 4th, 2017]
- ECDC says risk from contaminated CRISPR kits low - CIDRAP [Last Updated On: May 4th, 2017] [Originally Added On: May 4th, 2017]
- CRISPR Could Transform the Way We Diagnose Disease - Gizmodo [Last Updated On: May 4th, 2017] [Originally Added On: May 4th, 2017]
- A cancer gene also grows stem cells, CRISPR in monkey embryo ... - Speaking of Research [Last Updated On: May 5th, 2017] [Originally Added On: May 5th, 2017]
- New CRISPR Technique Can Potentially Stop Cancer In Its Tracks - Wall Street Pit [Last Updated On: May 6th, 2017] [Originally Added On: May 6th, 2017]
- CRISPR gene-editing tool targets cancer's "command center" - Gizmag - New Atlas [Last Updated On: May 7th, 2017] [Originally Added On: May 7th, 2017]
- Update: CRISPR - Radiolab [Last Updated On: May 7th, 2017] [Originally Added On: May 7th, 2017]
- Cambridge gene editing firm CRISPR to use delivery tech honed ... - Boston Business Journal [Last Updated On: May 9th, 2017] [Originally Added On: May 9th, 2017]
- Oxford Genetics licenses CRISPR tech to power synbio push - FierceBiotech [Last Updated On: May 10th, 2017] [Originally Added On: May 10th, 2017]
- What You Need to Know About the New CRISPR Cancer Treatment - BOSS Magazine [Last Updated On: May 11th, 2017] [Originally Added On: May 11th, 2017]
- CRISPR: The Future of Medicine and Human Evolution - in-Training [Last Updated On: May 12th, 2017] [Originally Added On: May 12th, 2017]
- Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual ... - GlobeNewswire (press... [Last Updated On: May 13th, 2017] [Originally Added On: May 13th, 2017]
- Pac-Man like CRISPR enzymes discovered - Lab News [Last Updated On: May 13th, 2017] [Originally Added On: May 13th, 2017]
- Coming age of CRISPR gene editing: What in heck is the 'Pink Chicken Project'? - Genetic Literacy Project [Last Updated On: May 15th, 2017] [Originally Added On: May 15th, 2017]
- Intellia moves closer to clinic with CRISPR tech - FierceBiotech [Last Updated On: May 15th, 2017] [Originally Added On: May 15th, 2017]
- Will CRISPR Technology Create a New "Human" Species? - Big Think [Last Updated On: May 15th, 2017] [Originally Added On: May 15th, 2017]
- Caribou Bioscience's CEO on CRISPR's legal and ethical challenges - TechCrunch [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- Cut Out the Hype: Gene Editing With CRISPR and the Truth about Superhuman 'Designer Babies' - WhatIsEpigenetics.com (blog) [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- CRISPR-Cas.org [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- Synthego's genetic toolkit aims to make CRISPR more accessible - TechCrunch [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- What is CRISPR? A Beginner's Guide | Digital Trends [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- Geneticists Enlist Engineered Virus and CRISPR to Battle Citrus Disease - Scientific American [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- Editas delays IND for Allergan-partnered CRISPR program - FierceBiotech [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- Easy DNA Editing Will Remake the World. Buckle Up - WIRED [Last Updated On: May 16th, 2017] [Originally Added On: May 16th, 2017]
- Can CRISPR feed the world? - Phys.org - Phys.Org [Last Updated On: May 19th, 2017] [Originally Added On: May 19th, 2017]
- Gene-editing tool 'CRISPR' gaining massive attention - KMOV.com [Last Updated On: May 19th, 2017] [Originally Added On: May 19th, 2017]
- Fixing the tomato: CRISPR edits correct plant-breeding snafu - Nature.com [Last Updated On: May 19th, 2017] [Originally Added On: May 19th, 2017]
- Beyond just promise, CRISPR is delivering in the lab today - The Conversation US [Last Updated On: May 20th, 2017] [Originally Added On: May 20th, 2017]
- What is CRISPR-Cas9, and will it change the world? | Alphr - Alphr [Last Updated On: May 20th, 2017] [Originally Added On: May 20th, 2017]
- Fixing the Tomato: CRISPR Edits Correct Plant-Breeding Snafu ... - Scientific American [Last Updated On: May 20th, 2017] [Originally Added On: May 20th, 2017]
- This UK Biotech uses CRISPR-Cas9 To Fight Bacterial Resistance - Labiotech.eu (blog) [Last Updated On: May 21st, 2017] [Originally Added On: May 21st, 2017]
- Can CRISPR feed the world? | Horizon: the EU Research ... - Horizon magazine [Last Updated On: May 21st, 2017] [Originally Added On: May 21st, 2017]
- Will this gene-editing tool cure the diseases of the future? - Sacramento Bee [Last Updated On: May 23rd, 2017] [Originally Added On: May 23rd, 2017]
- How the CRISPR-Cas9 System is Redefining Drug Discovery - Labiotech.eu (blog) [Last Updated On: May 23rd, 2017] [Originally Added On: May 23rd, 2017]
- Scientists are using gene editing to create the perfect tomato for your salad - Quartz [Last Updated On: May 24th, 2017] [Originally Added On: May 24th, 2017]
- Fine-tuning CRISPR to Create Popular Mouse Models - Technology Networks [Last Updated On: May 25th, 2017] [Originally Added On: May 25th, 2017]
- Scientists Are Using CRISPR To "Program" Living Cells - Futurism - Futurism [Last Updated On: May 25th, 2017] [Originally Added On: May 25th, 2017]
- CRISPR gene editing puts the brakes on cancer cells - Cosmos [Last Updated On: May 26th, 2017] [Originally Added On: May 26th, 2017]
- Watch This Scientist Brilliantly Explain CRISPR to Everyone from a Child to a Ph.D. - Patheos (blog) [Last Updated On: May 27th, 2017] [Originally Added On: May 27th, 2017]
- Using CRISPR gene editing to slow cancer growth | FierceBiotech - FierceBiotech [Last Updated On: May 27th, 2017] [Originally Added On: May 27th, 2017]
- How A Gene Editing Tool Went From Labs To A Middle-School Classroom - NPR [Last Updated On: May 27th, 2017] [Originally Added On: May 27th, 2017]
- In Just a Few Short Years, CRISPR Has Sparked a Research Revolution - Futurism [Last Updated On: May 29th, 2017] [Originally Added On: May 29th, 2017]
- CRISPR Is Taking Over Science, Breaks Out Of Labs And Invades Schools - EconoTimes [Last Updated On: May 30th, 2017] [Originally Added On: May 30th, 2017]
- Gene-editing technique scientists hope will cure cancer and all ... - The Independent [Last Updated On: May 30th, 2017] [Originally Added On: May 30th, 2017]
- CRISPR Gene-Editing Can Cause Hundreds of Unexpected ... - ScienceAlert [Last Updated On: May 30th, 2017] [Originally Added On: May 30th, 2017]